Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis

Current Medical Research and Opinion

Volumn 33, Issue 5, 2017, Pages 813-820

  Rajagopalan, Krithika ^a   Wade, Sally ^b   Meyer, Nicole ^c   Loebel, Antony ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Wade Outcomes Research and Consulting   (United States)

^c IBM WATSON HEALTH   (United States)

Author keywords

Adherence; atypical antipsychotic; retrospective analysis; schizophrenia; treatment discontinuation

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; HYPNOTIC AGENT; LURASIDONE; MOOD STABILIZER; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ALCOHOL ABUSE; ANXIETY; ANXIETY DISORDER; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; YOUNG ADULT; ECONOMICS; INSURANCE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LURASIDONE HYDROCHLORIDE; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; PIPERAZINES; QUETIAPINE FUMARATE; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; UNITED STATES;

EID: 85011672047     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1284656     Document Type: Article

References (38)

1. National Institutes of Health NIoMH. Mental Illness:Facts and Numbers. 2014; Available at:http://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml [Last accessed 22 April 2014]
2. Panish J, Karve S, Candrilli SD, Dirani R., Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharmaceut Health Serv Res 2013;4:29-39
3. Berger A, Edelsberg J, Sanders KN, et al. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge:a retrospective cohort study. BMC Psychiatry 2012;12:99
4. Markowitz M, Karve S, Panish J, et al. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry 2013;13:246
5. National Alliance on Mental Illness. Schizophrenia Fact Sheet. 2014. Available at:http://www.nami.org [Last accessed 29 2014]
6. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association.; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56
7. Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA., Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care 2005;11(8 Suppl):S254-S61
8. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
10. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo:a 6-month, open-label, extension study. J Clin Psychiatry 2013;74:507-15
11. Dolder CR, Lacro JP, Dunn LB, Jeste DV., Antipsychotic medication adherence:is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8
12. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989-95
13. Knapp M, King D, Pugner K, Lapuerta P., Non-adherence to antipsychotic medication regimens:associations with resource use and costs. Br J Psychiatry 2004;184:509-16
14. Law MR, Soumerai SB, Ross-Degnan D, Adams AS., A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
15. Liu-Seifert H, Adams DH, Kinon BJ., Discontinuation of treatment of schizophrenic patients is driven by poor symptom response:a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;3:21
16. Olfson M, Marcus SC, Wilk J, West JC., Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. Psychiatr Serv 2006;57:205-11
17. Svarstad BL, Shireman TI, Sweeney JK., Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
18. Velligan DI, Lam F, Ereshefsky L, Miller AL., Psychopharmacology:perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-7
19. Becker MA, Young MS, Ochshorn E, Diamond RJ., The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Pol Ment Health 2007;34:307-14
20. Offord S, Lin J, Mirski D, Wong B., Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
21. Weiden PJ, Kozma C, Grogg A, Locklear J., Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
22. Weiden PJ, Olfson M., Cost of relapse in schizophrenia. Schizophrenia Bull 1995;21:419-29
23. Sun SX, Liu GG, Christensen DB, Fu AZ., Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
24. Hart S, Hashemi L, Sobolewski CJ., Effect of a disposable automated suturing device on cost and operating room time in benign total laparoscopic hysterectomy procedures. JSLS 2013;17:508-16
25. Frank RG, Goldman HH, Hogan M., Medicaid and mental health:be careful what you ask for. Health Affairs 2003;22:101-13
26. Thomas MR, Waxmonsky JA, Gabow PA, et al. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. Psychiatr Serv 2005;56:1394-401
27. Deyo RA, Cherkin DC, Ciol MA., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
28. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence:terminology and definitions. Value Health 2008;11:44-7
29. Ren XS, Herz L, Qian S, et al. Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia. Neuropsychiatr Dis Treat 2009;5:491-8
30. Bali V, Kamble PS, Aparasu RR., Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder. J Manag Care Spec Pharm 2015;21:486-98
31. Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv 2011;62:1032-40
32. Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
33. Ndukwe HC, Nishtala PS., Time-to-first discontinuation, adherence and persistence in new users of second-generation antipsychotics. J Clin Psychopharmacol 2016;36:649-57
34. Gibson TB, Jing Y, Kim E, et al. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care 2010;19:40-7
35. Phan SV., Medication adherence in patients with schizophrenia. Int J Psychiatry Med 2016;51:211-19
36. Schneeweiss S, Gagne JJ, Glynn RJ, et al. Assessing the comparative effectiveness of newly marketed medications:methodological challenges and implications for drug development. Clin Pharmacol Ther 2011;90:777-90
37. Citrome L., Lurasidone for the acute treatment of adults with schizophrenia:what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses 2012;6:76-85
38. Puyat JH, Daw JR, Cunningham CM, et al. Racial and ethnic disparities in the use of antipsychotic medication:a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol 2013;48:1861-72